BCRX BioCryst Pharmaceuticals, Inc.
Price Chart
Executive Summary
BioCryst presented updated clinical data at EAACI 2026, including 48-week ORLADEYO pediatric results showing sustained HAE attack reductions and a post hoc analysis of Phase 1b/2 navenibart data supporting ongoing Phase 3 evaluation. The press release contains no new revenue, earnings, or financial guidance — it is a clinical data update with routine positive framing.
Actionable Insight
This is a routine medical conference data dump with no financial catalysts. ORLADEYO's core commercial story remains unchanged. Watch for Phase 3 navenibart (ALPHA-ORBIT) top-line data as the next binary catalyst — timing not stated in this release. No actionable trade signal from this filing alone.
Key Facts
- ORLADEYO 48-week data in pediatric HAE (APeX-P; n=29) showed median adjusted attack rate fell from 0.691/month (SOC) to 0.169/month on treatment.
- Attacks requiring professional care dropped from 22 (SOC 12wk) to 3 (first 12wk on ORLADEYO), reaching 0 in weeks 37-48.
- Phase 1b/2 ALPHA-STAR post hoc analysis (navenibart, n=29) showed consistent HAE attack reductions across baseline attack rate, BMI, and age subgroups.
- No severe or serious treatment-emergent adverse events reported for navenibart; most common TEAEs were headache, nasopharyngitis, and UTI.
- Multiple real-world evidence posters demonstrate ORLADEYO reduces healthcare utilization and improves patient satisfaction.
- No financial data, revenue, EPS, guidance, or material commercial updates were provided in this press release.
Financial Impact
No direct financial impact disclosed; clinical data updates support ongoing commercialization and pipeline value but do not change near-term revenue outlook for ORLADEYO.
Risk Factors
- No new commercial metrics or revenue guidance were provided — upside from this data is speculative.
- Navenibart Phase 3 results remain pending; could fail to replicate Phase 1b/2 findings in a larger, longer trial.
- Small n (29) and open-label design of APeX-P and ALPHA-STAR limit conclusiveness of these data.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310979 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
6d ago
|
8-K
| $9.06 $8.92 | ▼ −1.55% | ▼ −0.95% | $8.95 (−1.21%) |
|
Jun 12, 2026
6d ago
|
Press Release
| $8.70 $9.06 | ▲ +4.14% | ▲ +2.37% | $8.95 (+2.87%) |
|
May 19, 2026
4w ago
|
Insider Cluster
| $8.74 $8.37 | ▼ −4.23% | ▼ −4.43% | $8.95 (+2.40%) |
|
May 13, 2026
5w ago
|
144
| $9.60 $9.57 | ▼ −0.31% | ▼ −1.09% | $8.95 (−6.77%) |
|
May 6, 2026
6w ago
|
8-K
| $8.83 $8.90 | ▲ +0.79% | ▲ +1.12% | $8.95 (+1.36%) |
|
May 4, 2026
6w ago
|
8-K
| $9.20 $9.03 | ▼ −1.85% | ▼ −2.64% | $8.95 (−2.72%) |
|
Apr 23, 2026
8w ago
|
DEFA14A
| $8.94 $8.90 | ▼ −0.45% | ▼ −0.61% | $8.95 (+0.11%) |
|
Apr 15, 2026
9w ago
|
Press Release
| $9.44 $9.52 | ▲ +0.85% | ▲ +0.59% | $8.95 (−5.19%) |
|
Mar 16, 2026
13w ago
|
Insider Cluster
| $9.30 $9.21 | ▼ −0.97% | ▼ −1.24% | $8.95 (−3.76%) |
|
Feb 26, 2026
16w ago
|
8-K
| $7.90 $8.75 | ▲ +10.76% | ▲ +11.21% | $8.95 (+13.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access